sotigalimab

Also Known As:

APX005M

Networked: 9 relevant articles (0 outcomes, 5 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        sotigalimab: 9
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        sotigalimab: 9
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        sotigalimab: 9

Experts

1.	Alanio, Cécile: 2 articles (01/2022 - 01/2021)
2.	Bucktrout, Samantha: 2 articles (01/2022 - 01/2021)
3.	Byrne, Katelyn T: 2 articles (01/2022 - 01/2021)
4.	Cabanski, Christopher R: 2 articles (01/2022 - 01/2021)
5.	Chen, Richard O: 2 articles (01/2022 - 01/2021)
6.	Dugan, Ute: 2 articles (01/2022 - 01/2021)
7.	Fairchild, Justin: 2 articles (01/2022 - 01/2021)
8.	Fisher, George: 2 articles (01/2022 - 01/2021)
9.	Gherardini, Pier Federico: 2 articles (01/2022 - 01/2021)
10.	Hubbard-Lucey, Vanessa M: 2 articles (01/2022 - 01/2021)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 08/03/2023 - "We conducted a multi-center, open-label, phase II trial to evaluate the combination of sotigalimab 0.3mg/kg and nivolumab 360mg q3wk in patients with advanced melanoma following confirmed disease progression on anti-PD-1. " 01/01/2021 - "A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1." 08/03/2023 - "A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1."
2.	Disease Progression 08/03/2023 - "We conducted a multi-center, open-label, phase II trial to evaluate the combination of sotigalimab 0.3mg/kg and nivolumab 360mg q3wk in patients with advanced melanoma following confirmed disease progression on anti-PD-1. " 01/01/2021 - "APX005M was dose escalated (0.03, 0.1, or 0.3 mg/kg i.v.) with a fixed dose of cabiralizumab with or without nivolumab every 2 weeks until disease progression or intolerable toxicity. " 08/03/2023 - "A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1."
3.	Pancreatic Neoplasms (Pancreatic Cancer) 01/01/2022 - "Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial." 10/18/2022 - "Padron et al.1 studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. "
4.	Neoplasms (Cancer) 07/01/2021 - "APX005M is a highly potent inducer of innate and adaptive immune effector responses and represents a promising CD40 agonist antibody for induction of an effective anti-tumor immune response with a favorable safety profile." 03/15/2021 - "The reduction in tumor growth and ability to reprogram the tumor microenvironment in preclinical models lays the foundation for clinical development of agonistic CD40 antibodies (APX005M, ChiLob7/4, ADC-1013, SEA-CD40, selicrelumab, and CDX-1140) that are currently being evaluated in early phase clinical trials. "
5.	Adenocarcinoma 01/01/2021 - "APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma." 01/01/2021 - "APX005M and gemcitabine plus nab-paclitaxel, with or without nivolumab, is tolerable in metastatic pancreatic adenocarcinoma and shows clinical activity. " 01/01/2021 - "CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study." 01/01/2021 - "In this study, we aimed to evaluate the safety of combining APX005M (sotigalimab) with gemcitabine plus nab-paclitaxel, with and without nivolumab, in patients with pancreatic adenocarcinoma to establish the recommended phase 2 dose. "

Related Drugs and Biologics

1.	Nivolumab
2.	sotigalimab
3.	Monoclonal Antibodies
4.	Antibodies
5.	Gemcitabine
6.	130-nm albumin-bound paclitaxel
7.	selicrelumab
8.	cabiralizumab
9.	Toll-Like Receptors (Toll-Like Receptor)
10.	Interleukin-12 (IL 12)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics